EP0172007A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Stable liposomes with aqueous-soluble medicaments and methods for their preparation
Assignee: Syntex USA LLC
•
Filing: 1985-08-09
•
Granted: —
•
Expires: 2005-08-09
Abstract
Abstract A method is disclosed for preparing stable, high- capture-efficiency liposomes containing aqueous-soluble medicaments, by lyophilizing a liposome-forming lipid dissolved in a suitable organic solvent to form a lyophilized lipid, and hydrating the lyophilized lipid with an aqueous solution containing a suitable aqueous-soluble medicament.
Inventors
- 👤 Philip L. Felgner
- 👤 Deborah A. Eppstein
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-30 16:16
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/217; A61K38/215; A61K9/00; A61K9/10; A61K9/127; A61K9/1277
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
40 words
A method for preparing liposomes containing aqueous-soluble medicaments, which method comprises lyophilizing a liposome-forming lipid dissolved in a suitable organic solvent to form a lyophilized lipid; and hydrating the lyophilized lipid with an aqueous solution containing a suitable aqueous-soluble medicament.
Claim 2
Independent Claim
40 words
A method for preparing liposomes containing aqueous-soluble medicaments, which method comprises lyophilizing a liposome-forming lipid dissolved in a suitable organic solvent to form a lyophilized lipid; and hydrating the lyophilized lipid with an aqueous solution containing a suitable aqueous-soluble medicament.
Claim 3
Dependent Claim
13 words
The method of Claim 1 wherein said aqueous-soluble medicament is an active interferon.
Claim 4
Dependent Claim
13 words
The method of Claim 2 wherein said interferon is βIFN, αIFN or γIFN,
Claim 5
Dependent Claim
14 words
The method of Claim 3 wherein said βIFN is HuβIFN, preferably rHuβIFN ser17 .
Claim 6
Dependent Claim
29 words
An injectable, pharmaceutically acceptable suspension of liposomes encapsulating active interferon, wherein said liposomes remain near the injection site and release interferon over a period of 1 to 14 days.
Claim 7
Dependent Claim
29 words
An injectable, pharmaceutically acceptable suspension of liposomes encapsulating active interferon, wherein said liposomes remain near the injection site and release interferon over a period of 1 to 14 days.
Claim 8
Dependent Claim
31 words
Pharmaceutically acceptable suspension of liposomes encapsulating active interferon suitable for topical application, wherein said liposomes remain near the application site and release interferon over a period of 1 to 14 days.
Claim 9
Dependent Claim
31 words
Pharmaceutically acceptable suspension of liposomes encapsulating active interferon suitable for topical application, wherein said liposomes remain near the application site and release interferon over a period of 1 to 14 days.
Claim 10
Dependent Claim
19 words
The suspension of Claim 5 or Claim 6 wherein said suspension is formed by a method of Claim 2.
Claim 11
Dependent Claim
23 words
The suspension of Claim 5 or Claim 6 wherein said interferon is SIFN, aIFN or YIFN, preferably HuβIFN, most preferably rHuβIFN ser17 .
Claim 12
Dependent Claim
48 words
The suspension of any one of Claims 5 to 8 wherein said lipid is selected from phosphatidylcholine derivatives and phosphatidylglycerol derivatives, preferably a lipid mixture comprising distearoylphosphatidylcholine or diarachidoylphosphatidylcholine and dipalmitoylphosphotidylglycerol, most preferably a mixture comprising distearoylphosphatidylcholine or diarachidoylphosphatidylcholine and dipalmitoylphosphotidylglycerol in a molar ratio of about 7:3.
Claim 13
Dependent Claim
37 words
A pharmaceutically acceptable suspension of liposomes encapsulating active interferon prepared by a method of any one of Claims 2, 3 and 4, for use in effecting the sustained topical.administration of interferon to a mammal in need thereof.
Claim 14
Dependent Claim
15 words
The suspension of Claim 10 wherein said topical application is by nasal drops or aerosol.
Claim 15
Dependent Claim
12 words
The suspension of Claim 10 wherein said topical application is by suppository.
Claim 16
Dependent Claim
50 words
The suspension of any one of Claims 10, 11 and 12 wherein said lipid is selected from phosphatidylcholine derivatives and phosphatidylglycerol derivatives, preferably a lipid mixture comprising distearoylphosphatidylcholine or diarachidoylphosphatidylcholine and dipalmitoylphosphatidylglycerol, most preferably a lipid mixture comprising distearoylphosphatidylcholine or diarachidoylphosphatidylcholine and dipalmitoylphosphatidylglycerol in a molar ratio of about 7t3.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.